Drug intelligence / Profile preview

EPI-SK14

Development stage: Unknown
Lead developer: EpiPharm
Modality: Small Molecules
Administration: Topical

Overview

EPI-SK14 is a topical small molecule formulation of artemether, a semi-synthetic derivative of artemisinin, being developed by EpiPharm for the treatment of seborrheic keratosis (SK). While artemether is traditionally utilized as an antimalarial agent, its application in EPI-SK14 leverages its ability to induce apoptosis and inhibit the proliferation of keratinocytes, which are the primary cell type in seborrheic keratosis lesions. By targeting these benign skin tumors topically, EPI-SK14 aims to provide a non-invasive therapeutic alternative to physical removal methods such as cryotherapy or curettage. EpiPharm has completed Phase 1/2 clinical trials to evaluate the safety and efficacy of this formulation.

Other names: Artemether (topical formulation)

Beyond the preview

Go deeper on EPI-SK14.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EPI-SK14.

Explore the full profile